Sveriges Riksbank
Bid procedure, 2021-01-29 | |
Bonds | SWEDISH GOVERNMENT: 1053. SE0002829192. 2039-03-30 SWEDISH GOVERNMENT: 1056, SE0004517290, 2032-06-01 KINGDOM OF SWEDEN, XS2226974504, 2030-09-09 |
Bid date | 2021-01-29 |
Bid times | 09.00-10.00 (CET/CEST) on the Bid date |
Requested volume (corresponding nominal amount) | 1053: 500 mln SEK +/-250 mln SEK 1056: 500 mln SEK +/-250 mln SEK XS2226974504: 250 mln SEK +/-250 mln SEK |
Highest permitted bid volume (corresponding nominal amount) | 1053: 500 mln SEK per bid 1056: 500 mln SEK per bid XS2226974504: 250 mln SEK per bid |
Lowest permitted bid volume (corresponding nominal amount) | SEK 50 million per bid |
Expected allocation time | Not later than 10.15 (CET/CEST) on the Bid date |
Delivery and payment date | 2021-02-02 |
Delivery of bonds | To the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 |
Stockholm, 2021-01-22
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
Zealand Pharma17.10.2025 17:05:17 CEST | Press release
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom